Antibiotic Resistance Market Forecasts to 2030 – Global Analysis By Disease (Clostridium difficile infections, Hospital-acquired bacterial pneumonia, Complicated intra-abdominal infections, Community-acquired bacterial pneumonia, Acute bacterial skin and skin-structure infection, Bloodstream infection and Complicated urinary tract infections ), Pathogen (Baumannii, Pseudomonas aeruginosa, Enterococcus faecium, Hemophilus Influenzae, K. Pneumoniae, E. Coli, Streptococcus pneumonia, Clostridium difficile, Staphylococcus Aureus and Acinetobacter), Drug Class, Mechanism of Action, End User and By Geography.
According to Stratistics MRC, the Global Antibiotic Resistance Market is accounted for $8.75 billion in 2023 and is expected to reach $14.71 billion by 2030 growing at a CAGR of 7.7% during the forecast period. The drugs that are frequently used to treat a variety of infections are referred to as antibiotics. When bacteria endure genetic changes or mutations that allow them to live and grow even when exposed to antibiotics, antibiotic resistance develops, diminishing or completely removing the effectiveness of the drugs. As a result, infections brought on by these resistant bacteria become more challenging to treat, which causes illnesses to last longer, cost more money to treat, and may raise fatality rates.
According to the CDC, the incidence of antibiotic-resistant infections is more than 2.8 million in the U.S. The annual burden of the disease in the country is estimated between USD 21.0 billion to USD 34.0 billion. Globally, MRSA imposes a significant cost burden due to a high resistance rate of an average of 25.0% in developed countries and around 40% in developing regions.
Market DynamicsDriver
Increasing Prevalence of Antibiotic-Resistant Infections
The increasing prevalence of antibiotic-resistant infections is a critical driver of the antibiotic resistance market. Overuse and misuse of antibiotics have led to the emergence of resistant strains of bacteria, rendering conventional antibiotics less effective. This escalating resistance poses a serious threat to public health, resulting in prolonged illnesses, increased mortality rates, and higher healthcare costs. Infections caused by antibiotic-resistant bacteria often necessitate the use of more expensive and potentially less effective second-line treatments. Consequently, there is a growing demand for innovative antibiotics and alternative therapies to combat these resistant pathogens. The need to develop new and effective antibiotics is fueling research and development efforts, attracting investments, and driving collaborations within the pharmaceutical and healthcare sectors. These factors are responsible for market growth.
RestraintStringent regulatory standards
The antibiotic resistance market faces stringent regulatory requirements that can pose significant challenges for drug development and market entry. Regulatory agencies demand extensive clinical trials and thorough documentation of safety and efficacy to ensure the effectiveness of new antibiotics. Meeting these requirements necessitates substantial investments of time and resources, often resulting in prolonged development timelines and increased costs. These elements are hampering market demand.
OpportunityDevelopment of novel antibiotics
The development of novel antibiotics presents a significant opportunity within the antibiotic resistance market. With the rise of antibiotic-resistant bacterial strains, there is an emerging need for innovative drugs that can effectively combat these resilient pathogens. Investing in the development of novel antibiotics is not only a healthcare imperative but also a promising business opportunity. Additionally, public-private partnerships and collaborations are fostering a good environment for advancing antibiotic research, encouraging innovation, and expediting the development and commercialization of new antibiotics, driven by the potential market demand for effective antibiotics and the societal impact of mitigating antibiotic resistance.
ThreatOveruse and Misuse of Antibiotics
Overuse and misuse of antibiotics constitute a significant threat to the antibiotic resistance market. Over-prescription and inappropriate use of antibiotics, often driven by patient demand, a lack of proper diagnostic tools, or medical practitioners' prescribing habits, contribute to the development of antibiotic-resistant strains. When antibiotics are used unnecessarily or incorrectly, bacteria have a higher chance of developing resistance, rendering these drugs ineffective. These factors are responsible for decreasing market growth.
Covid-19 ImpactAntibiotic use and demand increased among COVID-19 patients early in the pandemic to treat secondary bacterial infections. Antibiotic resistance may occur as a result of the increased use. Additionally, there is a better understanding of the risks associated with antibiotic resistance and the necessity for appropriate and responsible antibiotic usage as a result of the increasing awareness among the general public, healthcare professionals, and politicians. The pandemic served as a reminder of the value of antibiotic management programmes, which encourage the responsible use of antibiotics and aid in the fight against antibiotic-resistant illnesses. Healthcare systems gave priority to such initiatives to make sure that antibiotics are only given when necessary and in sufficient quantities to stop the spread of illnesses that are resistant to therapy. Overall, the pandemic had a positive impact on global market demand.
The Tetracyclines segment is expected to be the largest during the forecast period
The Tetracyclines segment is estimated to hold the largest share. This has fuelled the demand for alternative treatment options and the development of novel antibiotics. Tetracyclines, a class of antibiotics used to treat a wide range of bacterial infections, have faced challenges due to the emergence of antibiotic-resistant strains. Additionally, healthcare organisations and regulatory bodies are promoting responsible antibiotic use and implementing stringent guidelines to curb the spread of resistance. While the tetracycline’s segment has ongoing research and collaborative efforts hold promise for addressing antibiotic resistance and ensuring effective treatment options for infectious diseases.
The Hospitals & Clinics segment is expected to have the highest CAGR during the forecast period
The Hospitals & Clinics segment is anticipated to have lucrative growth during the forecast period. The hospitals and clinics segment of the antibiotic resistance market plays a crucial role in managing and combating the challenges posed by antibiotic-resistant infections. As healthcare facilities are at the forefront of diagnosing and treating patients, they face the direct impact of antibiotic resistance. This segment encompasses hospitals, clinics, and other healthcare institutions that provide medical services. Healthcare professionals in these settings are actively involved in implementing antimicrobial stewardship programmes, promoting infection prevention and control measures, and optimising the use of antibiotics. Furthermore, hospitals and clinics contribute to surveillance efforts by monitoring the prevalence and patterns of antibiotic resistance and collaborating with researchers and regulatory bodies to develop strategies for combating this global health threat.
Region with largest shareAsia Pacific commanded the largest market share during the extrapolated period due to the high prevalence of infectious diseases in the area, extensive antibiotic use has resulted. It represents the greatest user of antibiotics in the world, which raises the possibility of developing diseases with antibiotic resistance. Antibiotic-resistant bacteria have emerged and spread as a result of improper usage of antibiotics, including overuse and misuse. Additionally, the Asia-Pacific area is a hub for the propagation of resistance due to its dense population and high load of diseases that are antibiotic-resistant. The growing awareness about antibiotic resistance and the need for effective interventions are driving efforts to combat the issue in the region.
Region with highest CAGRNorth America is expected to witness profitable growth over the projection period. North America region has a high prevalence of antibiotic resistance, with a significant burden of antibiotic-resistant infections reported. This is attributed to factors such as the overuse and misuse of antibiotics, both in healthcare settings and in the community. region also exhibits robust research and development activities focused on developing new antibiotics and alternative treatment options. Additionally, government initiatives and public-private partnerships in North America have played a crucial role in addressing antibiotic resistance through the implementation of antibiotic stewardship programmes and raising awareness about appropriate antibiotic use.
Key players in the marketSome of the key players in the Antibiotic Resistance Market include Basilea Pharmaceutica Ltd., Tetraphase Pharmaceuticals, Inc., Entasis therapeutics, Theravance Biopharma, Paratek Pharmaceuticals, Inc., Seres Therapeutics, Merck & Co. Inc., Achaogen Inc., Melinta Therapeutics, AbbVie, Inc., Johnson & Johnson, Pfizer Inc., Cipla Ltd., Bayer AG, AstraZeneca plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Roche Holding AG, Cubist Pharmaceuticals, Inc. and Mylan N.V.
Key DevelopmentsIn June 2023, BSI, the business improvement and Standards Company, launched a new global Minimized Risk of Antimicrobial Resistance (AMR) certification designed to promote and attest to the responsible manufacturing of antibiotics in the global supply chain.
In November 2022, Quadripartite launches a new platform to tackle antimicrobial resistance threat to human and animal health and ecosystems. The Antimicrobial Resistance Multi-Stakeholder Partnership Platform was launched today to ensure the growing threats and impacts of antimicrobial resistance are addressed globally.
In November 2022, Apollo announced the launch of an Antimicrobial Stewardship Programme (Apollo ASP). The programme will sensitize care providers on Antimicrobial Resistance (AMR), an issue leading to a public health problem.
In April 2022, Johnson & Johnson announced the opening of the J&J Satellite Center for Global Health Discovery (Satellite Center) at the University of Cape Town's Holistic Drug Discovery and Development (H3D).
Diseases Covered
• Clostridium difficile infections
• Hospital-acquired bacterial pneumonia
• Complicated intra-abdominal infections
• Community-acquired bacterial pneumonia
• Acute bacterial skin and skin-structure infection
• Bloodstream infection
• Complicated urinary tract infections
Pathogens Covered
• Baumannii
• Pseudomonas aeruginosa
• Enterococcus faecium
• Hemophilus Influenzae
• K. Pneumoniae
• E. Coli
• Streptococcus pneumoniae
• Clostridium difficile
• Staphylococcus Aureus
• Acinetobacter
Drug Classes Covered
• Tetracyclines
• Cephalosporins
• Oxazolidinones
• Combination therpaies
• Lipoglycopeptides
• Other Drug Classes
Mechanism of Actions Covered
• Cell Wall Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Protein Synthesis Inhibitors
• RNA synthesis inhibitors
• Other Mechanism of Actions
End Users Covered
• Hospitals & Clinics
• Homecare
• Research Organizations
• Other End Users
Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements